KẾT QUẢ PHÁC ĐỒ PACLITAXEL-CARBOPLATIN KẾT HỢP BEVACIZUMAB TRONG ĐIỀU TRỊ BƯỚC 1 UNG THƯ BIỂU MÔ TUYẾN PHỔI GIAI ĐOẠN IV

Abstract

Objectives: Describe clinical and laboratory features and assess treatment results of patients with stage IV adenocarcinoma lung cancer without EGFR mutations treated with paclitaxel/ carboplatin/ bevacizumab regimen. Patients and methods: Descriptive cohort study on 62 adenocarcinoma lung cancer patients without EGFR mutations treated with paclitaxel/ carboplatin/ bevacizumab regimen in first line setting at the National Cancer Hospital (K hospital) from January 2016 to April 2020. Primary study end-points included PFS. Secondary end-point was toxicity profile.  Results: The rate of patients achieved partial response and stable disease was 35.5% and 43.5% respectively. There were 21.0% of the patients had disease progression. The Median PFS was 7.0 months. Median overall survival was 15 months, and was associated with response status. Overall survival rate at 12 months was 66.13%, at 24 months was 20.97%. The most common toxicities included alopecia (82.3%), anemia (62.9%) peripheral neural toxicity (40.3%), neutropenia (38.6%), arthralgia (35.5%), thrombocytopenia (14.5%) and elevated liver enzymes (11.3%), hypertension (4,8). Most of the toxicities were at grade 1 or 2. Grade 3-4 toxicities were rare. Conclusion: Paclitaxel/ carboplatin/ bevacizumab regimen in first-line treatment for adenocarcinoma stage IV lung cancers without EGFR mutations yielded high response and disease control rates, improved PFS, OS with tolerable toxicities.